Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Helen Knight

Tracked across 2 events · 14 articles · First seen Mar 31, 2026 · Last active Sep 17, 2026

Sentiment
2
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 0
Regulatory
Impact: Helen Knight, director of medicines evaluation at United Kingdom — National Institute for Health and Care Research, commented on the compelling evidence from clinical trials supporting semaglutide's effectiveness.
Mar 31, 2026 · 7 articles
4 5
Regulatory
The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000…
Impact: NICE's director of medicines evaluation said the commercial solution and new assessment methods allowed the treatment to be provided on the NHS.
Sep 16, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Helen Knight live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.